Earnings ·
ARS Pharmaceuticals reports Q3 revenue of $37.7M and net loss of $(0.36) per share
SPRYARS Pharmaceuticals, Inc.
ARS Pharmaceuticals reported third-quarter 2026 total revenue of $37.7 million, driven by $33.4 million in U.S. net product revenue for neffy. The company posted a net loss of $35.6 million, or $(0.36) per share, compared to a net loss of $51.2 million, or $(0.52) per share, in the prior-year period. Operating expenses totaled $71.9 million, reflecting a 42% reduction in SG&A from the first-half average as the firm discontinued broad advertising. U.S. market share for neffy reached 5%, up from 4% in Q3 2025, with field-targeted accounts seeing 9% penetration. The company reaffirmed its path to cash flow breakeven by year-end 2027 and reported $138.4 million in cash and short-term investments as of September 30, 2026. ARS Pharmaceuticals is a commercial biopharmaceutical company focused on needle-free epinephrine treatments for severe allergic reactions.